These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 2754289

  • 21. [Levels of circulating tumor-associated glycoprotein (TAG-72) in patients with carcinoma using a novel tumor marker, CA 72-4].
    Ohuchi N, Matoba N, Taira Y, Takahashi K, Sakai N, Sato K, Fujita N, Mochizuki F, Nishihira T, Mori S.
    Gan To Kagaku Ryoho; 1988 Sep; 15(9):2767-72. PubMed ID: 3166366
    [Abstract] [Full Text] [Related]

  • 22. [Clinical significance of serum sialyl Tn antigen in patients with gynecological cancer. STN Study Group].
    Noda K, Shiota M, Tanizawa O, Inoue M, Tenjin Y, Sugishita T, Yakushiji M, Miyoshi T, Nozawa S, Sakuma T.
    Gan To Kagaku Ryoho; 1991 Jul; 18(8):1287-96. PubMed ID: 2069400
    [Abstract] [Full Text] [Related]

  • 23. [The clinical significance of thrombin-antithrombin III complex (TAT) and fibrinogen and fibrin degradation products (FDP) levels in ovarian cancer].
    Sawaguchi K, Hojo T, Nozaki S, Yabushita H, Noguchi M, Nakanishi M.
    Nihon Sanka Fujinka Gakkai Zasshi; 1992 Jan; 44(1):73-8. PubMed ID: 1541865
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. [Relationship between tumor markers and clinical symptoms in ovarian cancer].
    Yakushiji M, Nishimura H.
    Rinsho Byori; 1992 Apr; 40(4):354-8. PubMed ID: 1593760
    [Abstract] [Full Text] [Related]

  • 26. p16 expression in the female genital tract and its value in diagnosis.
    O'Neill CJ, McCluggage WG.
    Adv Anat Pathol; 2006 Jan; 13(1):8-15. PubMed ID: 16462152
    [Abstract] [Full Text] [Related]

  • 27. Significance of some tumor markers in differential diagnosis of ovarian tumor.
    Zakrzewska I, Borawska R, Poznański J, Maćkowiak B.
    Rocz Akad Med Bialymst; 1999 Jan; 44():235-43. PubMed ID: 10697438
    [Abstract] [Full Text] [Related]

  • 28. Measurement of a monoclonal-antibody-defined antigen (90K) in the sera of patients with ovarian cancer.
    Scambia G, Panici PB, Baiocchi G, Perrone L, Iacobelli S, Mancuso S.
    Anticancer Res; 1988 Jan; 8(4):761-4. PubMed ID: 3178164
    [Abstract] [Full Text] [Related]

  • 29. [A fundamental and clinical investigation of cancer antigen 130 (CA 130) in the field of obstetrics and gynecology].
    Inaba N, Okajima Y, Ota Y, Fukazawa I, Yamaguchi T, Sato N, Sudo H, Milanga M, Takamizawa H, Fujii S.
    Nihon Gan Chiryo Gakkai Shi; 1989 Oct 20; 24(10):2426-35. PubMed ID: 2614181
    [Abstract] [Full Text] [Related]

  • 30. [The clinical value of tissue polypeptide antigen in ovarian carcinoma].
    Wu L, Sun J, Wang X.
    Zhonghua Fu Chan Ke Za Zhi; 1998 Feb 20; 33(2):92-4. PubMed ID: 10682428
    [Abstract] [Full Text] [Related]

  • 31. Circulating mucins as tumor markers in ovarian cancer (review).
    Devine PL, McGuckin MA, Ward BG.
    Anticancer Res; 1992 Feb 20; 12(3):709-17. PubMed ID: 1622128
    [Abstract] [Full Text] [Related]

  • 32. [CA 125 (cancer antigen 125), a new tumor associated antigen recognized by monoclonal antibody].
    Suzuki H, Teshima K, Noda K.
    Gan To Kagaku Ryoho; 1984 Dec 20; 11(12 Pt 2):2719-23. PubMed ID: 6594978
    [Abstract] [Full Text] [Related]

  • 33. [Studies on clinical usefulness of new tumor markers of ovarian cancer, CA54/61 and CA602--III. Measurement of serum samples from patients with various benign or malignant diseases].
    Nozawa S, Udagawa Y, Sasaki H, Ito K, Akiya K, Terashima Y, Takamizawa H, Ohkura H, Fujimoto S, Hashimoto M.
    Gan To Kagaku Ryoho; 1994 May 20; 21(6):823-32. PubMed ID: 8185340
    [Abstract] [Full Text] [Related]

  • 34. [Significance of CA 125 antigen levels in patients with ovarian cancer].
    Shimizu Y, Fujiwara H, Akagaki E, Hirota K, Kono M, Irie T, Miura S, Okudaira Y.
    Gan To Kagaku Ryoho; 1986 Jan 20; 13(1):46-52. PubMed ID: 3455806
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. [The preparation and clinical use of a radioimmunoassay CA125 kit for the diagnosis of epithelial ovarian cancer].
    Liu W.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1992 Dec 20; 14(6):469-72. PubMed ID: 1303823
    [Abstract] [Full Text] [Related]

  • 37. [An early detection of the recurrence of serous cystadenocarcinoma of the ovary with the tumor marker CA125 levels].
    Usui N, Suzuki M, Takada M.
    Nihon Sanka Fujinka Gakkai Zasshi; 1992 Jun 20; 44(6):703-9. PubMed ID: 1506732
    [Abstract] [Full Text] [Related]

  • 38. [New technology of diagnosis of ovarian cancer].
    Terashima Y.
    Gan No Rinsho; 1988 Aug 20; 34(10):1427-31. PubMed ID: 2845169
    [Abstract] [Full Text] [Related]

  • 39. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
    Dong L, Cui H, Li XP, Sun LF, Chang XH, Liang XD, Zhu HL.
    Zhonghua Fu Chan Ke Za Zhi; 2008 Jan 20; 43(1):5-8. PubMed ID: 18366923
    [Abstract] [Full Text] [Related]

  • 40. [The clinical significance of serum sialyl Tn antigen levels in patients with gynecologic tumors].
    Shimizu C, Inoue M, Ogawa H, Ueda G, Tanizawa O.
    Nihon Sanka Fujinka Gakkai Zasshi; 1990 Nov 20; 42(11):1537-42. PubMed ID: 2273309
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.